News
News from us and our partners
News
News
Capital
News
Biovelocita
News
Crossover
News
Capital
News
In memory of Denis Lucquin, Sofinnova chairman
Sofinnova Partners closes Capital XI at €650M
Sofinnova Partners exceeds target with €165M biotech acceleration fund, Europe’s largest, with strong Pharma support
CEO spotlight: Thierry Abribat's third straight win
Johnson & Johnson to acquire Shockwave Medical
CEO spotlight: CinCor's Marc de Garidel
Tags
Topics
0 results
- News
TISSIUM secures €60 million to support commercial and clinical activities and platform expansion
- News
Micropep Files First Regulatory Submissions for Promisin™, a Novel Peptide Biofungicide with a New Mode of Action
- News
How a Sofinnova Partner's thesis became a $165M biotech
- News
Bionyra Pharma Launches with $165 million Oversubscribed Series A to Advance Clinical Stage Pipeline of Next Generation Biologics for Immune-Mediated Inflammatory Diseases
- News
Sitryx Completes Enrollment in Phase 1b Trial of First-in-Class Oral PKM2 Modulator SYX-5219 in Atopic Dermatitis
- News
F2G and Shionogi Announce Positive Topline Results from Global Phase 3 OASIS Study Evaluating Oral Olorofim Versus AmBisome® Followed by Standard of Care in Patients with Invasive Aspergillosis
- News
Germany’s top research institutions and venture capital investors unite behind spin-off framework
- News
Sofinnova Partners launches collaboration with AWS to scale AI across life sciences innovation
- News
Moon Surgical expands Maestro® platform into a multi-model physical AI platform with software Version 2.7
- News
Ingenix raises €13M led by Sofinnova to scale Modality Fusion AI
- Feature
2025 Impact Report: focusing on the future of industrial biotech
- News
P2 Science raises $23M to expand green chemistry platform
- News
HAYA Therapeutics doses first cohort in Phase 1 trial
- News
Tulyp Medical appoints Steve Motes as CEO
- News
Baxfendy approved in the US for hypertension